The DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index.
Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study
Abstract
Objective: Speculation remains that GH treatment is associated with increased neoplasia risk. Studies in GH-treated childhood cancer survivors suggested higher rates of second neoplasms, while cancer risk data for GH-treated and untreated hypopituitary adults have been variable. We present primary cancer risk data from the Hypopituitary Control and Complications Study (HypoCCS) with a focus on specific cancers, and assessment of recurrence rates for pituitary adenomas (PA) and craniopharyngiomas (CP). Design: Incident neoplasms during HypoCCS were evaluated in 8418 GH-treated vs 1268 untreated patients for primary malignancies, 3668 GH-treated vs 720 untreated patients with PA history, and 956 GH-treated vs 102 untreated patients with CP history. Methods: Using population cancer rates, standardised incidence ratios (SIRs) were calculated for all primary cancers, breast, prostate, and colorectal cancers. Neoplasm rates in GH-treated vs untreated patients were analysed after propensity score adjustment of baseline treatment group imbalances. Results: During mean follow-up of 4.8 years, 225 primary cancers were identified in GH-treated patients, with SIR of 0.82 (95% CI 0.71–0.93). SIRs (95% CI) for GH-treated patients were 0.59 (0.36–0.90) for breast, 0.80 (0.57–1.10) for prostate, and 0.62 (0.38–0.96) for colorectal cancers. Cancer risk was not statistically different between GH-treated and untreated patients (relative risk (RR)=1.00 (95% CI 0.70–1.41), P=0.98). Adjusted RR for recurrence was 0.91 (0.68–1.22), P=0.53 for PA and 1.32 (0.53–3.31), P=0.55 for CP. Conclusions: There was no increased risk for all-site cancers: breast, prostate or colorectal primary cancers in GH-treated patients during HypoCCS. GH treatment did not increase the risk of PA and CP recurrences.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,592
Reducing Bias in Observational Studies Using Subclassification on the Propensity Score
Rosenbaum, P. R., & Rubin, D. B. (1984) · Journal of the American Statistical Association · doi:10.1080/01621459.1984.10478078 · Cited by 3,082
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996
Renehan, A. G., Zwahlen, M., Minder, C., O'Dwyer, S. T., Shalet, S. M., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16044-3 · Cited by 1,697
Insulin-like growth factors and neoplasia
Pollak, M. N., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1387 · Cited by 1,463
Ma, J., Pollak, M. N., Giovannucci, E., Chan, J. M., Tao, Y., Hennekens, C. H., & Stampfer, M. J. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.620 · Cited by 1,119
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Samani, A. A., Yakar, S., LeRoith, D., & Brodt, P. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0001 · Cited by 1,005
Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study1
Orme, S. M., McNally, R. J. Q., Cartwright, R. A., & Belchetz, P. E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5007 · Cited by 805
(2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70095-4 · Cited by 652
Research works printed but not linked: 2
- Erfurth, 2001, Journal of Clinical Endocrinology & Metabolism, 86, 659
- Murray, 2002, Journal of Clinical Endocrinology & Metabolism, 87, 129, 10.1210/jc.87.1.129 · doi:10.1210/jc.87.1.129
Cited by
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Pathogenesis and Diagnosis of Growth Hormone Deficiency in Adults
Melmed, S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1817346 · Cited by 173
Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review
Gebauer, J., Higham, C., Langer, T., Denzer, C., & Brabant, G. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00092 · Cited by 161
Late endocrine effects of childhood cancer
Rose, S. R., Horne, V. E., Howell, J. C., Lawson, S. A., Rutter, M. M., Trotman, G. E., & Corathers, S. D. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.45 · Cited by 168
Long-Acting Growth Hormone Preparations – Current Status and Future Considerations
Miller, B. S., Velazquez, E. P., & Yuen, K. C. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz149 · Cited by 134
Metadata
- Authors
- Child, C. J., Conroy, D., Zimmermann, A. G., Woodmansee, W. W., Erfurth, E. M., & Robison, L. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Child, Christopher J
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-06
- Volume
- 172
- Issue
- 6
- Pages
- 779-790
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2111522495
- Semantic Scholar
- cb456e8c9ca45f672d60e277ee404312a71cd59c
- Cited by
- 58
- References
- 50
- Citations by year
- 2025: 4 · 2024: 2 · 2023: 7 · 2022: 8 · 2021: 3 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 10 · 2016: 6 · 2015: 3
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Keywords
- growth hormone therapy, hypopituitarism, pituitary adenoma recurrence, neoplasia risk, breast cancer, prostate cancer, colorectal cancer, pituitary adenoma, craniopharyngioma, treatment-related cancer risk, propensity score
- MeSH terms
- Adenoma, Adult, Breast Neoplasms, Craniopharyngioma, Female, Humans, Hypopituitarism, Male, Middle Aged, Neoplasm Recurrence, Local, Pituitary Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Incidence, Human Growth Hormone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study. https://app.cochat.ai/papers/10.1530/eje-14-1123
- The paper
- Child, C. J., Conroy, D., Zimmermann, A. G., Woodmansee, W. W., Erfurth, E. M., & Robison, L. L. (2015). Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study. European Journal of Endocrinology. https://doi.org/10.1530/eje-14-1123
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.